SCR-LIP-000421 · Claim · machine-readable JSON →
In premenopausal women with lipedema, serum endostatin (an angiogenesis inhibitor) was significantly reduced compared to controls (p=0.038), while adiponectin, chemerin, LBP, PCSK9, sCD163, sCD137, and IGFBP2 did not differ, suggesting altered vascular homeostasis without directly assessing varicose veins.
This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- low (GRADE)
- Evidence
- 1 source(s)
- Answers
- 0 question(s)
- Dates
- 2026-08-02 → 2026-08-02
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-08-02
Evidence over time
Evidence (1)
- Reduced Serum Endostatin in Premenopausal Women with Lipedema Suggests Altered Vascular Homeostasis. — Kempa S, Weiss TS, Tews HC, Prantl L, Müller M, Buechler C. (2026) ✓ verified — contextual · cross sectional · 2026 · reading confidence: high
“Reduced serum endostatin levels support a potential role for vascular dysfunction in the pathophysiology of lipedema.”
The study examines vascular dysfunction biomarkers in lipedema, addressing vascular pathophysiology broadly, but does not directly test the relationship between lipedema and varicose veins or clinical venous disease; it provides background
Context (PECO)
Answers these questions
- Not yet linked to a question.
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-08-02 — created · auto-ingested for SQ-LIP-000018
- 2026-11-20 — consolidated · SQ-LIP-000018: evidence moved to SCR-LIP-000684